Research ArticleOriginal Article

SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer

Qian Geng, Ruiting Xian, Yinjue Yu, Fengsheng Chen and Rong Li
Cancer Biology & Medicine April 2022, 19 (4) 468-485; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0501

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2018. CA-Cancer J Clin. 2018; 68: 7–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2018; 68: 394–424.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Torre LA,
    3. Bray F,
    4. Siegel RL,
    5. Ferlay J,
    6. Lortet-Tieulent J,
    7. Jemal A.
    Global cancer statistics, 2012. CA-Cancer J Clin. 2015; 65: 87–108.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. He RJ,
    3. Yu ZH,
    4. Zhang RY,
    5. Zhang ZY.
    Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin. 2014; 35: 1227–46.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Gu H,
    3. Neel BG.
    The “Gab” in signal transduction. Trends Cell Biol. 2003; 13: 122–30.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. Ostman A,
    3. Hellberg C,
    4. Bohmer FD.
    Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006; 6: 307–20.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Lluch A,
    3. Eroles P,
    4. Perez-Fidalgo JA.
    Emerging EGFR antagonists for breast cancer. Expert Opin Emerg Drugs. 2014; 19: 165–81.
    OpenUrl
  8. 8.
    2. Daemen A,
    3. Manning G.
    HER2 is not a cancer subtype but rather a driver found in all intrinsic subtypes and highly enriched in molecular apocrine tumors. Cancer Res. 2017; 77: 1.
    OpenUrlFREE Full Text
  9. 9.↵
    2. Press MF,
    3. Pike MC,
    4. Chazin VR,
    5. Hung G,
    6. Udove JA,
    7. Markowicz M, et al.
    Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993; 53: 4960–70.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Slamon DJ,
    3. Clark GM,
    4. Wong SG,
    5. Levin WJ,
    6. Ullrich A,
    7. McGuire WL.
    Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY). 1987; 235: 177–82.
    OpenUrl
  11. 11.
    2. Slamon DJ,
    3. Godolphin W,
    4. Jones LA,
    5. Holt JA,
    6. Wong SG,
    7. Keith DE, et al.
    Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, NY). 1989; 244: 707–12.
    OpenUrl
  12. 12.
    2. Owens MA,
    3. Horten BC,
    4. Da Silva MM.
    HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clinical Breast Cancer. 2004; 5: 63–9.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.
    2. Cortes J,
    3. Baselga J,
    4. Fumoleau P,
    5. Gelmon KA,
    6. Ross G,
    7. McNally V, et al.
    Pertuzumab and transtuzumab: exporatory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer. J Clin Oncol. 2010; 28: 1.
    OpenUrlFREE Full Text
  14. 14.↵
    2. Baselga J,
    3. Tripathy D,
    4. Mendelsohn J,
    5. Baughman S,
    6. Benz CC,
    7. Dantis L, et al.
    Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clinical Oncol. 1996; 14: 737–44.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Shen SH,
    3. Bastien L,
    4. Posner BI,
    5. Chretien P.
    A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature. 1991; 352: 736–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Johnson DJ,
    3. Pao LI,
    4. Dhanji S,
    5. Murakami K,
    6. Ohashi PS,
    7. Neel BG.
    Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med. 2013; 210: 1419–31.
    OpenUrlAbstract/FREE Full Text
  17. 17.
    2. Amin S,
    3. Kumar A,
    4. Nilchi L,
    5. Wright K,
    6. Kozlowski M.
    Breast Cancer cells proliferation is regulated by tyrosine phosphatase SHP1 through c-jun N-terminal kinase and cooperative induction of RFX-1 and AP-4 transcription factors. Mol Cancer Res. 2011; 9: 1112–25.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Shultz LD,
    3. Rajan TV,
    4. Greiner DL.
    Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 1997; 15: 302–7.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Long EO,
    3. Burshtyn DN,
    4. Clark WP,
    5. Peruzzi M,
    6. Rajagopalan S,
    7. Rojo S, et al.
    Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev. 1997; 155: 135–44.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    2. Nakamura K,
    3. Cambier JC.
    B cell antigen receptor (BCR)-mediated formation of a SHP-2-pp120 complex and its inhibition by Fc gamma RIIB1-BCR coligation. J Immunol. 1998; 161: 684–91.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Healy JI,
    3. Goodnow CC.
    Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol. 1998; 16: 645–70.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    2. Liu W,
    3. Innocenti F,
    4. Chen P,
    5. Das S,
    6. Cook EH Jr.,
    7. Ratain MJ.
    Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003; 9: 1009–12.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Blackwell KL,
    3. Burstein HJ,
    4. Storniolo AM,
    5. Rugo HS,
    6. Sledge G,
    7. Aktan G, et al.
    Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012; 30: 2585–92.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Subramaniam D,
    3. He AR,
    4. Hwang J,
    5. Deeken J,
    6. Pishvaian M,
    7. Hartley ML, et al.
    Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Curr Cancer Drug Targets. 2014; 14: 775–93.
    OpenUrl
  25. 25.↵
    2. Wang MN,
    3. Hu YZ,
    4. Yu T,
    5. Ma XL,
    6. Wei XW,
    7. Wei YQ.
    Pan-HER-targeted approach for cancer therapy: mechanisms, recent advances and clinical prospect. Cancer Lett. 2018; 439: 113–30.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Wu YF,
    3. Li R,
    4. Zhang JY,
    5. Wang G,
    6. Liu B,
    7. Huang XF, et al.
    Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2. Onco Targets Ther. 2015; 8: 2577–87.
    OpenUrl
  27. 27.↵
    2. Li J,
    3. Guan HY,
    4. Gong LY,
    5. Song LB,
    6. Zhang N,
    7. Wu JH, et al.
    Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008; 14: 6996–7003.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Luo WR,
    3. Fang WY,
    4. Li SY,
    5. Yao KT.
    Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Cancer. 2012; 131: 1863–73.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Wu C,
    3. Sun M,
    4. Liu L,
    5. Zhou GW.
    The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003; 306: 1–12.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.
    2. Liu CY,
    3. Chen KF,
    4. Chao TI,
    5. Chu PY,
    6. Huang CT,
    7. Huang TT, et al.
    Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. J Mol Med. 2017; 95: 965–75.
    OpenUrl
  31. 31.
    2. Wen LZ,
    3. Ding K,
    4. Wang ZR,
    5. Ding CH,
    6. Lei SJ,
    7. Liu JP, et al.
    SHP-1 Acts as a tumor suppressor in hepatocarcinogenesis and HCC progression. Cancer Res. 2018; 78: 4680–91.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Rodriguez-Ubreva FJ,
    3. Cariaga-Martinez AE,
    4. Cortes MA,
    5. Romero-De Pablos M,
    6. Ropero S,
    7. Lopez-Ruiz P, et al.
    Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene. 2010; 29: 345–55.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Sun TT,
    3. Aceto N,
    4. Meerbrey KL,
    5. Kessler JD,
    6. Zhou CS,
    7. Migliaccio I, et al.
    Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011; 144: 703–18.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    2. Schwartz AM,
    3. Henson DE,
    4. Chen DC,
    5. Rajamarthandan S.
    Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size a study of 161 708 cases of breast cancer from the SEER program. Arch Pathol Lab Med. 2014; 138: 1048–52.
    OpenUrl
  35. 35.↵
    2. Voduc KD,
    3. Cheang MCU,
    4. Tyldesley S,
    5. Gelmon K,
    6. Nielsen TO,
    7. Kennecke H.
    Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28: 1684–91.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Lemmon MA,
    3. Schlessinger J.
    Cell signaling by receptor tyrosine kinases. Cell. 2010; 141: 1117–34.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.
    2. Warren CM,
    3. Landgraf R.
    Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal. 2006; 18: 923–33.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.
    2. Yarden Y.
    The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37 Suppl 4: S3–8.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Seshacharyulu P,
    3. Ponnusamy MP,
    4. Haridas D,
    5. Jain M,
    6. Ganti AK,
    7. Batra SK.
    Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16: 15–31.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Roberts PJ,
    3. Der CJ.
    Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26: 3291–310.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.
    2. Meng XQ,
    3. Wu JX,
    4. Pan CC,
    5. Wang H,
    6. Ying XF,
    7. Zhou Y, et al.
    Genetic and epigenetic down-regulation of MicroRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology. 2013; 145: 426–36.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    2. Cano A,
    3. Perez-Moreno MA,
    4. Rodrigo I,
    5. Locascio A,
    6. Blanco MJ,
    7. del Barrio MG, et al.
    The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000; 2: 76–83.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    2. Carpenter G,
    3. Cohen S.
    Epidermal growth factor. Annu Rev Biochem. 1979; 48: 193–216.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.
    2. Yarden Y,
    3. Sliwkowski MX.
    Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127–37.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    2. Koboldt DC,
    3. Fulton RS,
    4. McLellan MD,
    5. Schmidt H,
    6. Kalicki-Veizer J,
    7. McMichael JF, et al.
    Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61–70.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    2. Pitteri SJ,
    3. Amon LM,
    4. Buson TB,
    5. Zhang YZ,
    6. Johnson MM,
    7. Chin A, et al.
    Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res. 2010; 70: 8598–606.
    OpenUrlAbstract/FREE Full Text
  47. 47.
    2. Ioachim E,
    3. Kamina S,
    4. Athanassiadou S,
    5. Agnantis NJ.
    The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res. 1996; 16: 3141–7.
    OpenUrlPubMed
  48. 48.
    2. Ruiz C,
    3. Seibt S,
    4. Al Kuraya K,
    5. Siraj AK,
    6. Mirlacher M,
    7. Schraml P, et al.
    Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer. 2006; 118: 2190–4.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.
    2. Lee HJ,
    3. Seo AN,
    4. Kim EJ,
    5. Jang MH,
    6. Kim YJ,
    7. Kim JH, et al.
    Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer. 2015; 112: 103–11.
    OpenUrlCrossRefPubMed
  50. 50.
    2. Nieto Y,
    3. Nawaz F,
    4. Jones RB,
    5. Shpall EJ,
    6. Nawaz S.
    Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol. 2007; 25: 4405–13.
    OpenUrlAbstract/FREE Full Text
  51. 51.
    2. Klijn JG,
    3. Berns PM,
    4. Schmitz PI,
    5. Foekens JA.
    The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13: 3–17.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    2. Rimawi MF,
    3. Shetty PB,
    4. Weiss HL,
    5. Schiff R,
    6. Osborne CK,
    7. Chamness GC, et al.
    Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010; 116: 1234–42.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords